Clinical Trials List
2013-03-01 - 2020-12-31
Phase III
Terminated5
ICD-10D00.2
Carcinoma in situ of stomach
ICD-9230.2
Carcinoma in situ of stomach
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Ann-Lii Cheng Division of Hematology & Oncology
- 林育麟 Division of Hematology & Oncology
- TA-CHEN HUANG Division of Hematology & Oncology
- 呂理駿 Division of Hematology & Oncology
- Chia-Chi Lin Division of Hematology & Oncology
- SUNG-HSIN KUO Division of Hematology & Oncology
- YU-YUN SHAO Division of Hematology & Oncology
- Chih-Hung Hsu Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- Chiun Hsu Division of Hematology & Oncology
- SHIH-HUNG YANG Division of Hematology & Oncology
- 林宗哲 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Wen-Chi Chou Division of Hematology & Oncology
- Chi-Ting Liau Division of Hematology & Oncology
- Wen-Chi Shen Division of Hematology & Oncology
- Yung-Chang Lin Division of Hematology & Oncology
- Hung-Chih Hsu Division of Hematology & Oncology
- 曹振輝 Division of Hematology & Oncology
- Tsai-Sheng Yang Division of Hematology & Oncology
- Chia-Hsun Hsieh Division of Hematology & Oncology
- Tse-Ching Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Completed
Co-Principal Investigator
- Chung-Pin Li Division of Radiation Therapy
- 方文良 Division of Radiation Therapy
- Ming-Huang Chen Division of Radiation Therapy
- Rheun-Chuan Lee Division of Radiation Therapy
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Yu-Min Yeh Division of Hematology & Oncology
- Yan-Shen Shan Division of General Surgery
- Shang-Yin Wu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Completed
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
24 participants
-
Global
780 participants